Research programme: anticancer therapeutics - SK Drug Development Center
Alternative Names: YKPAGLatest Information Update: 10 Jul 2009
Price :
$50 *
At a glance
- Originator SK Bio-Pharmaceuticals
- Developer SK Drug Development Center
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 22 Jun 2005 Preclinical trials in Cancer in South Korea (unspecified route)